Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.92
Nov 20 • 3:59 PM ET Dollar change-0.45 Percentage change(-8.38%)
Aftermarket Close
5.05
Aftermarket • 6:24 PM ET Dollar change+0.13 Percentage change(2.64%)
Nov 19, 7:06 AMKazia said its cash, August offering proceeds and September Sovargen milestone payment are expected to fund planned operations for at least 12 months.
Index
-
Market Cap
62.43M
Enterprise Value
20.04M
Income
-27.49M
Sales
0.07M
Book/sh
1.98
Cash/sh
3.34
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Jan 06, 1999
P/E
-
Forward P/E
-
PEG
-
P/S
891.93
P/B
2.49
P/C
1.47
P/FCF
-
EV/EBITDA
-
EV/Sales
286.35
Quick Ratio
2.33
Current Ratio
2.33
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-4.15
EPS next Y
-1.47
EPS next Q
-0.22
EPS this Y
-12.37%
EPS next Y
-38.15%
EPS next 5Y
-20.36%
EPS past 3/5Y
54.06% 32.93%
Sales past 3/5Y
- -64.07%
EPS Y/Y TTM
66.25%
Sales Y/Y TTM
163.68%
EPS Q/Q
63.73%
Sales Q/Q
163.68%
Insider Own
14.01%
Insider Trans
0.00%
Inst Own
54.89%
Inst Trans
17.06%
ROA
-115.28%
ROE
-279.44%
ROIC
-109.45%
Gross Margin
-
Oper. Margin
-30374.11%
Profit Margin
-39128.22%
SMA20
-30.92%
SMA50
-41.06%
SMA200
-53.36%
Trades
Shs Outstand
12.69M
Shs Float
10.91M
52W High
17.40 -71.72%
52W Low
4.86 1.23%
Volatility
15.61% 10.42%
ATR (14)
0.72
RSI (14)
23.35
Beta
2.46
Rel Volume
2.48
Avg Volume
295.40K
Volume
732,087
Perf Week
-25.68%
Perf Month
-39.03%
Perf Quarter
-62.73%
Perf Half Y
-63.98%
Perf YTD
-28.59%
Perf Year
-34.22%
Perf 3Y
-87.25%
Perf 5Y
-99.13%
Perf 10Y
-98.57%
Prev Close
5.37
Price
4.92
Change %
-8.38%
Consensus
Strong Buy
Avg. Price Target
$29.75
Implied Upside
+504.7%
Analysts9incl. previous ratings
Rating Distribution9 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 30, 2026Initiated
NNeedham
Buy$27+448.8%
Oct 21, 2026Initiated
GGuggenheim
Buy$35+611.4%
Oct 20, 2026Initiated
LLeerink Partners
Outperform$30+509.8%
Aug 13, 2026Initiated
CCanaccord Genuity
Buy$29+489.4%
Jul 01, 2026Initiated
BBTIG Research
Buy$34+591.1%
Jun 11, 2026Initiated
LLake Street
Buy$32+550.4%
Apr 15, 2026Initiated
LLaidlaw
Buy$25+408.1%
Feb 06, 2025Initiated
MMaxim Group
Buy$3-39.0%
Oct 14, 2021Initiated
MMaxim Group
Buy$18+265.9%
Jan 05, 2021Initiated
HH.C. Wainwright
Buy$17+245.5%
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
M.D.Dr. John Edwin Friend II
B.Com.Ms. Elissa C. Hansen ACSA
VP of Finance & ControllerMr. Jeffrey Bonacorda
Chief Financial OfficerMr. James E. Levine
Chief Scientific OfficerDr. Sudha Rao